Avallano, an AI-enabled clinical research company, announced the appointment of Michael A. Ibara, PharmD., as Chief Strategy Officer (CSO). Dr. Ibara will lead the company's global strategic initiatives to transform the clinical trial sector with leading-edge technology solutions.
Dr. Ibara will lead the launch of Avallano's generative AI technologies, aimed at enhancing clinical research by addressing the challenges faced by patients, sites, and sponsors in executing clinical trials. Avallano’s solutions include personalized patient chat services, AI-driven medical information processing, founded on a market-leading approach to global privacy and patient empowerment. He’ll guide the company in balancing regulatory compliance requirements with the capabilities of explainable AI. Explainable AI helps users understand complex AI models and determine what factors influence decision-making.
"Michael’s extensive experience in the biopharmaceutical industry and his innovative approach to data and clinical operations make him the perfect fit for Avallano," said Paul Della Maggiora, Co-Founder and CEO. "We have already benefited from Michael’s strategic vision as an advisor and confident that his leadership will help us achieve our ambitious goals and continue to provide exceptional service to our clients."
Prior to joining Avallano Dr. Ibara served as Chief Data Officer at Elligo Health Solutions, he created an innovative approach to utilize electronic health record (EHR) data for clinical trial feasibilities and operations. In addition to developing the first-ever effort to automate the collection of adverse events directly from EHRs, he has held senior leadership positions in large biopharmaceutical and CRO organizations. Dr. Ibara holds a Pharm.D. from the University of Michigan and a Fellowship from the University of North Carolina and Burroughs Wellcome Co.
"I am delighted to join Avallano at such an exciting time in the company's growth," said Dr. Ibara. "I look forward to working with the team to develop AI-driven solutions to improve clinical research and deliver innovative solutions to help patients get better value from participating in clinical trials."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!